Trial Profile
An Open Label, Phase 1B Safety Evaluation of Patritumab (U31287) in Combination With Cetuximab Plus Platinum Containing Therapy In Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Patritumab (Primary) ; Carboplatin; Cetuximab; Cisplatin
- Indications Carcinoma; Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Daiichi Sankyo Inc
- 16 Oct 2018 Results published in the Clinical Cancer Research
- 23 Aug 2016 Status changed from active, no longer recruiting to completed.
- 11 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.